Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PERSONALIS, INC.

(PSNL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Personalis : Expands Leadership Team With Appointment of Robert Bruce, Vice President of Reimbursement

10/13/2021 | 09:06am EST

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the appointment of Robert Bruce to the newly created position of Vice President of Reimbursement.

“We are very pleased to welcome Bob and his impressive public and private payer reimbursement strategy skill set to the Personalis team,” said John West, Chief Executive Officer. “He brings over 25 years of experience in all aspects of reimbursement execution within clinical molecular diagnostic testing, including offerings for Molecular Residual Disease assessment and monitoring.”

Mr. Bruce joins Personalis from Clinical Genomics, where he served as VP Reimbursement and Interim Chief Financial Officer. Prior to Clinical Genomics, Mr. Bruce provided reimbursement and financial consulting services to a range of private and public companies after serving in senior management roles with Enterix and Binax. Mr. Bruce holds a Bachelor of Arts degree in East Asian Studies from Princeton University and an MBA degree from the School of Management at Yale University.

“Personalis’ growth into clinical laboratory testing will offer providers new and innovative options to better understand the molecular basis of their cancer patients’ disease,” said Mr. Bruce. “I look forward to leading this effort and working collaboratively with the clinical and payer communities to provide patients with access to the industry-leading molecular diagnostic tests developed by my new Personalis colleagues.”

About Personalis, Inc.

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis® NeXT PlatformTM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. To enable cancer and population sequencing, the Personalis Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Forward-Looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, the company’s business opportunities, leadership or growth, market acceptance or potential reimbursement for the company’s tests, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.


ę Business Wire 2021
All news about PERSONALIS, INC.
11/18Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conferenc..
BU
11/12Personalis Named to Inc.'s 2021 Best-Led Companies List
BU
11/11Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th A..
BU
11/11Personalis to Present New Data at the Society for Immunotherapy of Cancer 36th Annual M..
CI
11/08Morgan Stanley Downgrades Personalis to Equalweight from Overweight, Adjusts Price Targ..
MT
11/04Personalis Q3 Net Loss Widens Despite Revenue Growth, Tightens Loss Guidance; Stock Ris..
MT
11/04PERSONALIS : Q3 Earnings Snapshot
AQ
11/04PERSONALIS, INC. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
11/04Personalis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended S..
CI
11/04Earnings Flash (PSNL) PERSONALIS Posts Q3 Revenue $22.3M, vs. Street Est of $22.2M
MT
More news
Analyst Recommendations on PERSONALIS, INC.
More recommendations
Financials (USD)
Sales 2021 85,1 M - -
Net income 2021 -67,3 M - -
Net cash 2021 287 M - -
P/E ratio 2021 -8,00x
Yield 2021 -
Capitalization 548 M 548 M -
EV / Sales 2021 3,07x
EV / Sales 2022 5,38x
Nbr of Employees 235
Free-Float 98,1%
Chart PERSONALIS, INC.
Duration : Period :
Personalis, Inc. Technical Analysis Chart | PSNL | US71535D1063 | MarketScreener
Technical analysis trends PERSONALIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 12,24 $
Average target price 32,00 $
Spread / Average Target 161%
EPS Revisions
Managers and Directors
John S. West President, Chief Executive Officer & Director
Aaron Tachibana Chief Financial Officer
Jonathan J. MacQuitty Chairman
Richard O. Chen Chief Scientific Officer
Xavier Paliard Vice President-Immunology, Research & Development
Sector and Competitors
1st jan.Capi. (M$)
PERSONALIS, INC.-66.57%548
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298